Evogene and Tel Aviv University Collaborate to Boost AI-Driven Drug Discovery Initiatives
Introduction
In a significant move to advance the realm of drug discovery, Evogene Ltd. and the Blavatnik Center for Drug Discovery (BCDD) at Tel Aviv University have announced a collaborative initiative aimed at enhancing the development of small-molecule drugs. This innovative partnership, launched on July 8, 2026, promises to leverage advanced artificial intelligence technology along with experimental infrastructure to accelerate drug discovery processes.
Combining Expertise for Enhanced Outcomes
Evogene, a leader in computational chemistry, is renowned for its generative design capabilities, particularly in the pharmaceutical and agricultural sectors. The BCDD at Tel Aviv University is dedicated to bridging the gap between academic research and therapeutic application. The partnership, facilitated by Ramot — the university's tech transfer company — intends to support researchers and entrepreneurs within Israel's vibrant academic landscape who are tackling complex medical challenges.
The initiative recognizes the struggle faced by many researchers: despite having a thorough understanding of potential disease targets, they often lack the resources necessary to transition their findings into tangible drug development programs. By integrating Evogene’s AI-driven computational tools such as ChemPass AI™ with BCDD’s experimental and translational capabilities, the collaboration aims to streamline the process of drug discovery.
The Design-Make-Test-Analyze Framework
At the core of this collaborative framework is a comprehensive Design-Make-Test-Analyze (DMTA) approach. This integrated process facilitates the evaluation of promising projects originating from Israeli academic institutions. Selected research initiatives will gain access to Evogene’s proprietary AI tools to design and optimize novel small molecules, while BCDD will employ its state-of-the-art facilities to validate these designs through rigorous experimental testing.
This streamlined approach is crucial as many early-stage drug candidates fail due to the absence of combined computational and experimental resources. The collaboration aims to provide an environment conducive to enhancing development efficiency, minimizing risks, and improving the chances for commercial success of emerging drug candidates.
Statements from Leadership
Ofer Haviv, President and CEO of Evogene, expressed optimism regarding the collaboration, emphasizing the potential it holds for addressing the barriers that researchers face in drug development. He stated, “Israel's academic institutions generate world-class discoveries and novel therapeutic targets. However, many entrepreneurs and researchers face significant hurdles in transforming these scientific insights into viable drug development programs. Through this collaboration with the Blavatnik Center for Drug Discovery, we are creating a unique framework that combines advanced AI-driven computational chemistry with world-class experimental validation capabilities.”
Leah Klapper, Managing Director of BCDD, echoed these sentiments, highlighting the center’s commitment to transitioning groundbreaking academic research into tangible patient treatments. “By partnering with Evogene, and leveraging their cutting-edge ChemPass AI™ engine, we can provide researchers and entrepreneurs with a comprehensive drug discovery pipeline.” Klapper believes this partnership will fortify the capacity of academic ventures to achieve successful therapeutic programs, ultimately enhancing patient outcomes.
Conclusion
The collaboration between Evogene and the Blavatnik Center for Drug Discovery illustrates a promising step forward in the field of drug discovery. By combining computational prowess and experimental validation, this initiative is set to redefine how academic research can translate into meaningful therapeutic advancements, potentially transforming the landscape of drug development in Israel and beyond. Researchers interested in small-molecule therapeutics, particularly those focusing on complex proteins or molecular glues, are encouraged to engage with the BCDD for potential project support. Together, this partnership aims to forge a path towards innovative medical solutions that can impact patients worldwide.
In a significant move to advance the realm of drug discovery, Evogene Ltd. and the Blavatnik Center for Drug Discovery (BCDD) at Tel Aviv University have announced a collaborative initiative aimed at enhancing the development of small-molecule drugs. This innovative partnership, launched on July 8, 2026, promises to leverage advanced artificial intelligence technology along with experimental infrastructure to accelerate drug discovery processes.
Combining Expertise for Enhanced Outcomes
Evogene, a leader in computational chemistry, is renowned for its generative design capabilities, particularly in the pharmaceutical and agricultural sectors. The BCDD at Tel Aviv University is dedicated to bridging the gap between academic research and therapeutic application. The partnership, facilitated by Ramot — the university's tech transfer company — intends to support researchers and entrepreneurs within Israel's vibrant academic landscape who are tackling complex medical challenges.
The initiative recognizes the struggle faced by many researchers: despite having a thorough understanding of potential disease targets, they often lack the resources necessary to transition their findings into tangible drug development programs. By integrating Evogene’s AI-driven computational tools such as ChemPass AI™ with BCDD’s experimental and translational capabilities, the collaboration aims to streamline the process of drug discovery.
The Design-Make-Test-Analyze Framework
At the core of this collaborative framework is a comprehensive Design-Make-Test-Analyze (DMTA) approach. This integrated process facilitates the evaluation of promising projects originating from Israeli academic institutions. Selected research initiatives will gain access to Evogene’s proprietary AI tools to design and optimize novel small molecules, while BCDD will employ its state-of-the-art facilities to validate these designs through rigorous experimental testing.
This streamlined approach is crucial as many early-stage drug candidates fail due to the absence of combined computational and experimental resources. The collaboration aims to provide an environment conducive to enhancing development efficiency, minimizing risks, and improving the chances for commercial success of emerging drug candidates.
Statements from Leadership
Ofer Haviv, President and CEO of Evogene, expressed optimism regarding the collaboration, emphasizing the potential it holds for addressing the barriers that researchers face in drug development. He stated, “Israel's academic institutions generate world-class discoveries and novel therapeutic targets. However, many entrepreneurs and researchers face significant hurdles in transforming these scientific insights into viable drug development programs. Through this collaboration with the Blavatnik Center for Drug Discovery, we are creating a unique framework that combines advanced AI-driven computational chemistry with world-class experimental validation capabilities.”
Leah Klapper, Managing Director of BCDD, echoed these sentiments, highlighting the center’s commitment to transitioning groundbreaking academic research into tangible patient treatments. “By partnering with Evogene, and leveraging their cutting-edge ChemPass AI™ engine, we can provide researchers and entrepreneurs with a comprehensive drug discovery pipeline.” Klapper believes this partnership will fortify the capacity of academic ventures to achieve successful therapeutic programs, ultimately enhancing patient outcomes.
Conclusion
The collaboration between Evogene and the Blavatnik Center for Drug Discovery illustrates a promising step forward in the field of drug discovery. By combining computational prowess and experimental validation, this initiative is set to redefine how academic research can translate into meaningful therapeutic advancements, potentially transforming the landscape of drug development in Israel and beyond. Researchers interested in small-molecule therapeutics, particularly those focusing on complex proteins or molecular glues, are encouraged to engage with the BCDD for potential project support. Together, this partnership aims to forge a path towards innovative medical solutions that can impact patients worldwide.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.